MedTrace Logo

Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC

NCT07035392 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2025-06-25

No results posted yet for this study

Summary

This study is a single arm, prospective, multicenter clinical trial, and eligible patients will receive the following treatment regimen: Adebrelimab combined with chemotherapy.The study includes a screening period (from the signing of informed consent by the subjects to no more than 28 days before the first medication, imaging examinations are allowed to be performed within 28 days before the first medication, and tumor tissue biopsy is allowed to be archived within 6 months before the first medication), a treatment period (including neoadjuvant and surgical treatment), and a follow-up period (including safety follow-up and survival follow-up).

Conditions

Interventions

DRUG

Adebrelimab

Adebrelimab 1200mg，ivgtt，D1，Q3W

DRUG

chemotherapy

Queue A (lung squamous cell carcinoma patients): Albumin paclitaxel 260mg/m2, ivgtt，D1 , Q3W Carboplatin AUC=5, D1，Q3W Queue B (lung adenocarcinoma patients): Pemetrexed 500 mg/m2, ivgtt，D1，Q3W Carboplatin AUC=5, D1，Q3W

Sponsors & Collaborators

  • Zhangzhou Municipal Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-20
Primary Completion
2026-12-01
Completion
2026-12-01

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07035392 on ClinicalTrials.gov